



Millendo Therapeutics to Present at J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., January 3, 2017 – [Millendo Therapeutics, Inc.](#), a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 3:00 p.m. PST in San Francisco, CA.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases caused by hormone dysregulation. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are advancing two product candidates in five indications: MLE4901, designed to address Polycystic Ovary Syndrome (PCOS) and Vasomotor Symptoms (VMS), and ATR-101 for the treatment of Classic Congenital Adrenal Hyperplasia (CAH), Endogenous Cushing's Syndrome (CS), and Adrenocortical Carcinoma (ACC). www.millendo.com

###

Media Contact:

Casey R. Doucette, Ph.D.
MacDougall Biomedical Communications
+1 781 235 3060
cdoucette@macbiocom.com

Investor Contact:

Christina Tartaglia
Stern Investor Relations
+1 212 362 1200
christina@sternir.com